Nanvuranlat is under clinical development by J-Pharma and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Nanvuranlat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Nanvuranlat overview

Nanvuranlat (JPH-203) is under development for the treatment of the solid tumor and biliary tract cancer. It is administered through an intravenous and oral route. The drug candidate is a low molecular weight compound that acts by targeting L-type amino acid transporter1 (LAT1). It was also under development for the treatment of colon cancer.

J-Pharma overview

J-Pharma is a pharmaceutical company that develops original inhibitors of L-type amino acid transporter 1 (LAT1) for the treatment of advanced cancer. The company’s products portfolio includes namburrat, OKY-034, LAT1 inhibitor, NKO-028 and 035. It offers drugs for various cancers which include biliary tract cancer, pancreatic cancer, solid cancer and autoimmune disease in the form intravenous injection and oral administration. The company also carries out different phases of clinical trails. J-Pharma is headquartered in Yokohama, Kanagawa, Japan.

For a complete picture of Nanvuranlat’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.